These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18353448)

  • 1. New endogenous CXC chemokine ligands as potential targets in lung emphysema.
    Folkerts G; Kraneveld AD; Nijkamp FP
    Trends Pharmacol Sci; 2008 Apr; 29(4):181-5. PubMed ID: 18353448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2.
    de Kruijf P; Lim HD; Overbeek SA; Zaman GJ; Kraneveld AD; Folkerts G; Leurs R; Smit MJ
    Eur J Pharmacol; 2010 Sep; 643(1):29-33. PubMed ID: 20599927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
    Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
    Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins.
    Kaneider NC; Agarwal A; Leger AJ; Kuliopulos A
    Nat Med; 2005 Jun; 11(6):661-5. PubMed ID: 15880119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
    Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
    J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.
    Cunha TM; Barsante MM; Guerrero AT; Verri WA; Ferreira SH; Coelho FM; Bertini R; Di Giacinto C; Allegretti M; Cunha FQ; Teixeira MM
    Br J Pharmacol; 2008 May; 154(2):460-70. PubMed ID: 18362895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
    Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a new interleukin-8 receptor in bovine species.
    Lahouassa H; Rainard P; Caraty A; Riollet C
    Mol Immunol; 2008 Feb; 45(4):1153-64. PubMed ID: 17727952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR2 antagonists for the treatment of pulmonary disease.
    Chapman RW; Phillips JE; Hipkin RW; Curran AK; Lundell D; Fine JS
    Pharmacol Ther; 2009 Jan; 121(1):55-68. PubMed ID: 19026683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR2--the receptor to hit?
    Reutershan J
    Drug News Perspect; 2006 Dec; 19(10):615-23. PubMed ID: 17299604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The missing link: chemokine receptors and tissue matrix breakdown in COPD.
    Smit JJ; Lukacs NW
    Trends Pharmacol Sci; 2006 Nov; 27(11):555-7. PubMed ID: 17000010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
    Nicholls DJ; Tomkinson NP; Wiley KE; Brammall A; Bowers L; Grahames C; Gaw A; Meghani P; Shelton P; Wright TJ; Mallinder PR
    Mol Pharmacol; 2008 Nov; 74(5):1193-202. PubMed ID: 18676678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody.
    Boyles JS; Beidler CB; Strifler BA; Girard DS; Druzina Z; Durbin JD; Swearingen ML; Lee LN; Kikly K; Chintharlapalli S; Witcher DR
    MAbs; 2020; 12(1):1831880. PubMed ID: 33183151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
    Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
    Busch-Petersen J
    Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.